Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (Diluted Average) (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Shares Outstanding (Diluted Average) data on record, last reported at $172.3 million in Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 92.44% to $172.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $172.3 million, a 92.44% increase, with the full-year FY2025 number at $98.3 million, up 314.6% from a year prior.
  • Shares Outstanding (Diluted Average) reached $172.3 million in Q1 2026 per IKT's latest filing, up from $98.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for IKT hit a ceiling of $172.3 million in Q1 2026 and a floor of $4.2 million in Q3 2022.
  • A 5-year average of $38.0 million and a median of $6.9 million in 2024 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 83.2% in 2022, then surged 1312.1% in 2025.
  • Tracing IKT's Shares Outstanding (Diluted Average) over 5 years: stood at $4.2 million in 2022, then skyrocketed by 42.74% to $6.0 million in 2023, then surged by 293.35% to $23.7 million in 2024, then soared by 314.6% to $98.3 million in 2025, then surged by 75.27% to $172.3 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for IKT at $172.3 million in Q1 2026, $98.3 million in Q4 2025, and $90.1 million in Q3 2025.